TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01535222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO-2010
Description: MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO-2010
Description: MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO-2010
Description: MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO-2010
Description: MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO-2010
Description: MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available NaCl
Study: NCT02728999

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Steep Trendelenburg
Description: •Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decreased Trendelenburg
Description: •Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure.
Study: NCT01447017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPK-060
Description: DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DPK-060 ear drops
Description: Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
Study: NCT00870662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFS System
Description: AFS System with patient specific flow rate
Study: NCT03978442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Cognitive Behavioral Therapy (CBT)
Description: 12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Cognitive Behavioral Therapy (CBT)
Description: 12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: 12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: 12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Abstinence Reinforcement Therapy
Description: Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoked Contingency Management
Description: Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
Study: NCT00127985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-methyl-prednisolone
Description: iv, 2 mg/kg/day, qid
Study: NCT06666582

Intervention type: DRUG
Intervention: Paclitaxel and ramucirumab
Description: Second-line treatment with paclitaxel/ramucirumab vs other regimens

Intervention type: DRUG
Intervention: Paclitaxel and ramucirumab
Description: Second-line treatment with paclitaxel/ramucirumab vs other regimens
Study: NCT02737787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1 Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Vaccine
Description: Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.
Study: NCT00986583

Intervention type: DRUG
Group type: OTHER
Intervention: Succinylcholine
Description: Succinylcholine will be administered pre-induction over a period of 5 seconds
Study: NCT02908802

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probiotics capsules without the active ingredient
Study: NCT01052285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
Study: NCT00083109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin
Description: Given IV
Study: NCT00002835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate (BLM)
Study: NCT01052285

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
Study: NCT00002835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Arm 1, Course 3, IV over 1 hour on day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (ARA-C)
Description: Arm 1, Course 3, every 12 hours on days -5 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: During Course 1, IV continuously; Course 2, IV continuously on days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Study: NCT01478750

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of fat (sunflower oil), emulsified
Description: 40 ml sunflower oil, in the presence of the emulsifier tween-80.
Study: NCT00002835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study: NCT02253524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: 50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
Study: NCT00002835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride (DHAD)
Description: Arm 1, Course 2, IV on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.
Study: NCT01478750

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of fat (sunflower oil), emulsified
Description: 40 ml sunflower oil, in the presence of the emulsifier tween-80.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of fat (sunflower oil), emulsified
Description: 40 ml sunflower oil, in the presence of the emulsifier tween-80.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of fat (sunflower oil), emulsified
Description: 40 ml sunflower oil, in the presence of the emulsifier tween-80.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of nasoduodenal tube
Description: A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of nasoduodenal tube
Description: A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of nasoduodenal tube
Description: A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of nasoduodenal tube
Description: A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
Study: NCT00072189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00002835

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study: NCT02726295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E. coli Nissle 1917(Mutaflor®)
Study: NCT02215265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative radiotherapy
Description: Postoperative radiotherapy (PORT)
Study: NCT02726295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04489056

Intervention type: GENETIC
Intervention: Swabs for microbiome analysis
Description: After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.

Intervention type: GENETIC
Intervention: Swabs for microbiome analysis
Description: After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
Study: NCT01436500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water with 5% Dextrose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water with 5% Dextrose
Study: NCT01482286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Restriction
Description: Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch.
Study: NCT03055507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Addition of ibuprofen to standard pain regimen.
Study: NCT02215265

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Description: Postoperative radiotherapy (PORT)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative radiotherapy
Description: Postoperative radiotherapy (PORT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Description: Postoperative radiotherapy (PORT)
Study: NCT01919411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Description: Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
Study: NCT03055507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 mg
Description: Standard analgesic provided post-operatively to patients undergoing sinus surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Description: Standard analgesic provided post-operatively to patients undergoing sinus surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 Mg Oral Tablet
Description: Standard PRN medication offered post-operatively for breakthrough pain
Study: NCT01919411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm will receive 7 days of placebo after surgery.
Study: NCT00144300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirapex
Description: Standard marketed product dispensed according to manufacturer's guidelines
Study: NCT00127985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 6-methyl-prednisolone
Description: iv, 2 mg/kg/day, qid
Study: NCT02402660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK-001
Description: Daily, oral administration for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, oral administration for 24 months
Study: NCT04170894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periods of Apnea
Description: Periods of apnea throughout atrial fibrillation ablation.
Study: NCT03055507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyCODONE 5 Mg Oral Tablet
Description: Standard PRN medication offered post-operatively for breakthrough pain
Study: NCT02547987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
Study: NCT04170894

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm - No Periods of Apnea
Description: Standard of care atrial fibrillation ablation.
Study: NCT01370642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir
Description: Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Study: NCT02095379

Intervention type: OTHER
Intervention: oligosecretary
Description: not abvailable
Study: NCT01370642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir
Description: Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to vaniprevir
Description: Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
Study: NCT05741970

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
Study: NCT02671721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Compliance
Description: PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transpulmonary Pressure
Description: We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
Study: NCT03630562

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aqueous humor samples collection
Description: In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
Study: NCT02375477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Given educational presentation
Study: NCT01501253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 2.5/40mg
Description: fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 2.5/80mg
Description: Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Amlodipine 2.5mg
Description: S-Amlodipine 2.5mg monotherapy
Study: NCT00466167

Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexol Extended Release